Chakra Biotech Sdn Bhd (Chakra) is a Malaysian company establishing world-class drug candidate screening through behavioural based in vivo rodent testing. Chakra NBSL will address the needs of the global pharmaceutical and biotech industry for the accurate, timely and inexpensive screening of new drugs for their potential usefulness in the area of central nervous system (CNS) disorders.

Companies developing CNS drugs for any disease face high risks of false positive and false negative signals from conventional screening. They often push poor drugs into clinical development or fail to see the full potential of useful drugs.

They will offer their service on a fee for service and through risk based agreements which allow us to share the risks and rewards of drug discovery with our customers.

Chakra is proud of its BioNexus status and will pursue their strategic and financial goals as a vibrant part of Malaysia’s emerging biotech sector. The research program for further behavioural screens and validation of existing screens will promote Malaysia as a center for neurobehavioral research.

We have a capable team to unlock the value potential of their intellectual property assets and build a valuable company. Their expertise in the areas of animal husbandry, behavioral screening, drug development and business development will build a strong link in the value chain in the Malaysian environment.